Summary of ceftaroline fosamil clinical trial studies and clinical safety

Clinical Infectious Diseases

Volumn 55, Issue SUPPL. 3, 2012, Pages

  File, Thomas M ^a,b   Wilcox, Mark H ^c,d   Stein, Gary E ^e  

^a Northeastern Ohio Medical University   (United States)

^b SUMMA HEALTH SYSTEM   (United States)

^c LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

^d UNIVERSITY OF LEEDS   (United Kingdom)

^e MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ASPARTATE AMINOTRANSFERASE; AZTREONAM; CEFOPERAZONE; CEFOTETAN; CEFTAROLINE; CEFTAROLINE FOSAMIL; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; VANCOMYCIN;

ACUTE CHOLECYSTITIS; ACUTE KIDNEY FAILURE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANAPHYLAXIS; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACTERIAL SKIN DISEASE; BLOOD TOXICITY; BURN INFECTION; CELLULITIS; CHOLESTASIS; COMMUNITY ACQUIRED PNEUMONIA; CONFUSION; CREATININE CLEARANCE; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EOSINOPHILIA; EPILEPTIC STATE; FOOD AND DRUG ADMINISTRATION; GALLSTONE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEMOLYTIC ANEMIA; HUMAN; IN VITRO STUDY; LIVER FUNCTION; LIVER FUNCTION TEST; LIVER TOXICITY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MULTIDRUG RESISTANCE; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; SEIZURE; SERUM SICKNESS; SIDE EFFECT; SKIN ABSCESS; SKIN INFECTION; STREPTOCOCCUS PNEUMONIAE; SUPERINFECTION; THROMBOCYTOPENIA; TREATMENT RESPONSE; TREMOR; URTICARIA; VOMITING; WOUND INFECTION;

EID: 84865232800     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis559     Document Type: Article

References (30)

1. File TM. Community-acquired pneumonia. Lancet 2003; 362:1991-2001.
2. Hoyert DL, Heron MP, Murphy SL, Kung HC. Deaths: final data for 2003. Natl Vital Stat Rep 2006; 54:1-120.
3. DeFrances CJ, Lucas CA, Buie VC, Golosinskiy A. 2006 National hospital discharge survey. Natl Health Stat Report 2008; 5:1-20.
4. Agency for Healthcare Research and Quality. Pneumonia is the most common reason for hospitalization. 2008. Available at: http://www.ahrq.gov/research/ sep08/0908RA40.htm. Accessed 26 June 2012.
5. File TM Jr, Marrie TJ. Burden of community-acquired pneumonia in North American adults. Postgrad Med 2010; 122:130-41.
6. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44(Suppl 2):S27-72.
7. Guidance for Industry Community-Acquired Bacterial Pneumonia: Developing Drugs for Treatment. Available at: http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM123686.pdf. Accessed 26 June 2012.
8. File TM Jr, Low DE, Eckburg PB, et al. Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia. Clin Infect Dis 2010; 51:1395-405.
9. Forest Laboratories, Inc. Teflaro. Package insert. 2010. Available at: http://www.frx.com/pi/Teflaro-pi.pdf. Accessed 26 June 2012.
10. Moisan H, Pruneau M, Malouin F. Binding of ceftaroline to penicillin-binding proteins of Staphylococcus aureus and Streptococcus pneu-moniae. J Antimicrob Chemother 2010; 65:713-6.
11. Nicholson SC, Welte T, File TM, Strauss RS, Michiels B. A randomized, double-blind trial comparing ceftobiprole medocaril with ceftri-axone with our without linezolid for the treatment of patients with community-acquired pneumonia requiring hospitalization. Inter J Antimicro Agents 2012; 39:240-6.
12. Pallin DJ, Egan DJ, Pelletier AJ, Espinola JA, Hooper DC, Camargo CA Jr. Increased US emergency department visits for skin and soft tissue infections, and changes in antibiotic choices, during the emergence of community-associated methicillin-resistant Staphylococcus aureus. Ann Emerg Med 2008; 51:291-8.
13. Wilcox MH, Corey GR, Talbot GH. CANVAS 2: The second phase III, randomized double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother 2010; 65:iv53-65.
14. Corey GR, Wilcox MH, Talbot GH. CANVAS 1: The first phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother 2010; 65(Suppl 4):iv41-51.
15. Corey GR, Wilcox M, Talbot GH, et al. Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vanco-mycin plus aztreonam in complicated skin and skin-structure infection. Clin Infect Dis 2010; 51:641-50.
16. Frazee BW, Lynn J, Charlebois ED, Lambert L, Lowery D, Perdreau-Remington F. High prevalence of methicillin-resistant Staphylococcus aureus in emergency department skin and soft tissue infections. Ann Emerg Med 2005; 45:311-20.
17. Grundmann H, Aires-de-Sousa M, Boyce J, Tiemersma E. Emergence and resurgence of meticillin-resistant Staphylococcus aureus as a public-health threat. Lancet 2006; 368:874-85.
18. Moran GJ, Krishnadasan A, Gorwitz RJ, et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 2006; 355:666-74.
19. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 2005; 41:1373-406.
20. Food and Drug Administration. Ceftaroline fosamil for the treatment of community-acquired bacterial pneumonia and complicated skin and skin structure infections. Briefing document for Anti-Infective Drugs Advisory Committee meeting, September 7, 2010. Available at: http://www.fda.gov/downloads/ advisorycommittees/committeesmeeti ngmaterials/drugs/anti- infectivedrugsadvisorycommittee/ucm224656.pdf Accessed 26 June 2012.
21. Miller LG, Perdreau-Remington F, Bayer AS, et al. Clinical and epide-miologic characteristics cannot distinguish community-associated methicillin-resistant Staphylococcus aureus infection from methicillin- susceptible S. aureus infection: a prospective investigation. Clin Infect Dis 2007; 44:471-82.
22. Corrado ML. Integrated safety summary of CANVAS 1 and 2 trials: phase III, randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother 2010; 65(Suppl 4):iv67-71.
23. Rank DR, Friedland HD, Laudano JB. Integrated safety summary of FOCUS 1 and FOCUS 2 trials: phase III randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with community-acquired pneumonia. J Antimicrob Chemother 2011; 66:iii53-9.
24. Kelkar PS, Li JT. Cephalosporin allergy. N Engl J Med 2001; 345:804-9.
25. Panagiotidis G, Backstrom T, Asker-Hagelberg C, Jandourek A, Weintraub A, Nord CE. Effect of ceftaroline on normal human intestinal microflora. Antimicrob Agents Chemother 2010; 54:1811-4.
26. Sattler FR, Weitekamp MR, Ballard JO. Potential for bleeding with the new beta-lactam antibiotics. Ann Intern Med 1986; 105:924-31.
27. Zhanel GG. Cephalosporin-induced nephrotoxicity: does it exist? DICP 1990; 24:262-5.
28. Grill MF, Maganti R. Cephalosporin-induced neurotoxicity: clinical manifestations, potential pathogenic mechanisms, and the role of elec-troencephalographic monitoring. Ann Pharmacother 2008; 42:1843-50.
29. Brown SJ, Desmond PV. Hepatotoxicity of antimicrobial agents. Semin Liver Dis 2002; 22:157-67.
30. Riccobene T, Su S, Rank D. A single-and multiple-dose study to determine the safety, tolerability, and pharmacokinetics (PK) of ceftaro-line fosamil and NXL104 administered by intravenous (IV) infusion to healthy subjects [abstract A2-546]. In: Program and abstracts of the 51st ICAAC conference (Chicago). Washington, DC: ICAAC, 2011.